CSPC Pharmaceutical Group (01093.HK): Batoclimab Injection (subcutaneous injection) has obtained a drug registration certificate issued by the National Medical Products Administration.

Zhitong Finance APP News, CSPC Pharmaceutical Group (01093.HK) announced that the batoclimab injection (subcutaneous injection) (trade name: Enlida) (the Product) licensed and introduced by the company's subsidiary CSPC NBP Pharmaceutical Co., Ltd. from Harbour BioMed (Shanghai) Co., Ltd. has obtained the drug registration certificate issued by China's National Medical Products Administration (NMPA), for use in combination with conventional drugs for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG).